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lar events may underly the pathogenesis of the differentTargeting -Synuclein
“protein aggregation” diseases.in Parkinson’s Disease Parkinson’s disease is the most common human neu-
rodegenerative movement disorder and affects 1% of
the elderly population. Although symptomatic treatment
strategies are available, PD has remained a noncurable
disease [5]. Primary clinical symptoms of PD are brady--Synuclein aggregation into fibrils is associated with
kinesia, resting tremor, muscular rigidity, and difficultythe pathogenesis of Parkinson’s disease (PD). Li et al.
with balance. PD is neuropathologically characterizedprovide strong evidence that rifampicin interacts with
by a marked and progressive degeneration of dopami--synuclein and inhibits its fibrillization [1]. Rifampicin
nergic neurons and by the presence of fibrillar cyto-could be a promising candidate for therapeutic appli-
plasmatic inclusions (Lewy bodies [LBs]) and dystrophiccation for PD.
neurites (Lewy neurites [LNs]) in the substantia nigra
region of the brain [6]. Although the loss of dopamine
Sometimes an observation may produce a hypothetical neurons is certainly related to the major clinical symp-
link between two apparently unrelated events. For ex- toms of PD, the causes and the pathogenesis of this
ample, the observation by McGeer et al. and Namba et multifactorial disease as well as that of related “synuclei-
al. that anti-leprosy-treated elderly patients have less nopathies” are still largely unknown.
dementia and senile plaques in their brains than non- The major components of both LBs and LNs are fibril-
treated patients has created a link between the anti- lar aggregates of -synuclein [6, 7]. -Synuclein is a
leprosy drug rifampicin and neurodegenerative diseases widely expressed, neuronal presynaptic protein that ap-
[2, 3]. How this hypothesis has been pursued and what pears to play a role in membrane-associated processes
might be the potential consequences for PD and other and synaptic plasticity and has been linked to learning
cell-degenerative diseases will be discussed here. and development processes [6]. While the mechanism(s)
In vivo protein aggregation into fibrillar deposits is of formation of LBs and LNs and their association with
strongly associated with cell degeneration and the PD is (are) yet not understood, several lines of evidence
pathogenesis of a number of progressive cell-degenera- suggest that -synuclein fibrillization is associated with
tive diseases. These include fatal neurodegenerative PD [6, 8]. Similarily to other protein aggregation dis-
diseases such as Alzheimer’s disease (AD), Parkinson’s eases, both neurotoxic and neuroprotective roles have
disease (PD), Huntington’s disease (HD), the transmissa- been attributed to the endproducts of -synuclein
ble spongiform encephalopathies (TSEs or prion dis- aggregation, the fibrillar -synuclein deposits [6, 8].
eases), the pancreatic  cell degenerative disease type -Synuclein fibril formation in vitro proceeds via the
II diabetes (T2D), and several other localized or systemic conversion of the 140 amino acid residue protein, that
amyloidoses [4]. In all these conditions, a disease-spe- appears to be “natively unfolded,” into ordered,  sheet-
cific polypeptide or protein aggregates into fibrillar de- rich oligomers also termed “protofibrils” [8]. -Synuclein
protofibrils or alternatively folded/assembled oligomersposits. Recent evidence suggests that common molecu-
Previews
1477
Figure 1. Potential Pathways for -Synuclein
Fibrillization and Its Inhibition by Rifampicin
(A) Simplified schematic representation of
possible molecular events in the fibrillization
pathway of -synuclein and possibly of other
amyloidogenic polypeptides or proteins. Mono-
meric -synuclein aggregates—possibly fol-
lowing formation of a partially folded inter-
mediate state—into soluble,  sheet-rich
oligomers (i.e., protofibrils) that will subse-
quently transform into fibrils [1, 8, 9, 15]. Alter-
natively, formation of oligomers may also pro-
ceed off-pathway (green arrows).
(B) Possible effects of rifampicin on fibrilliza-
tion of -synuclein: According to the findings
and suggestions of Li et al. [1], rifampicin (Rif)
may tightly and, possibly, covalently (dashed
line between Rif and the protein) bind mono-
meric -synuclein and its oligomeric form(s)
(in-, or off-pathway oligomers). The oligomers
may thus become “stabilized” and unable to
transform into fibrils.
(C) Possible effects of rifampicin on fibril dis-
assembly of -synuclein: According to the
findings of Li et al. [1], rifampicin disassem-
bles -synuclein fibrils and may bind—
possibly covalently—to the oligomers that are generated during disassembly of fibrils. Both the quaternary structure and the potential
neurotoxicity of the oligomeric and fibrillar -synuclein forms are still unknown. The different colors of the boxes around the oligomers indicate
potential differences between the oligomers with regard to quaternary structure and neurotoxicity.
have been suggested to be neurotoxic [8, 9]. Protofibrils oligomers and fibrils. These results suggest that rifampi-
cin prevents the formation of  sheet aggregates ofgradually transform into fibrils that may thus act as
sequestors of neurotoxic species [9]. Independently of -synuclein. Size-exclusion chromatography (SEC),
Thioflavin T binding, and electron microscopy suggestthe nature of the neurotoxic species, the process of
-synuclein fibrillization appears to be strongly linked that the interaction of rifampicin with soluble-synuclein
results in the stabilization of -synuclein monomers andto neurodegeneration. Therefore, identifying molecular
strategies/factors that may interfere with and/or inhibit soluble oligomers. In addition, rifampicin was found to
be able to dissociate -synuclein fibrils into soluble, this process is a reasonable approach to both under-
stand the molecular causes of PD and to develop novel sheet-rich oligomers. As rifampicin easily degrades and/
or oxidizes into quinone products in aqueous solution,treatment concepts. Li et al. describe in this issue their
efforts toward these targets [1]. rifampicin solutions incubated under aerobic or anaero-
bic conditions were also studied, and solutions con-In the course of their studies to investigate a potential
link between senile dementia and rifampicin, Tomiyama taining oxidative degradation products were signifi-
cantly more “potent.” SEC analysis indicated thatet al. earlier found that rifampicin inhibits fibrillization
and neurotoxicity of -amyloid peptide (A) [10–12]. A rifampicin tightly binds -synuclein mono- and oligo-
mers. The authors propose that in fact rifampicin mightis the major consituent of senile plaques, and its fibrilli-
zation is strongly associated with neurodegeneration in covalently bind -synuclein, possibly, via reaction of its
naphthoquinone form with amino groups of lysine sideAD. In addition, rifampicin inhibited cell toxicity of islet
amyloid polypeptide (IAPP), which is the amyloidogenic chain to form a Schiff base.
This hypothesis and the results of the rifampicin stud-polypeptide in T2D. As oxidative stress is associated
with cell degeneration, these effects were first attributed ies presented here (Figure 1) are in line with the results
of other studies: Zhu et al. have very recently shownto the potential antioxidative effect of rifampicin, which
possesses a naphthohydroquinone or naphthoquinone that the flavonoid baicalein also inhibits -synuclein fi-
brillization, stabilizes a partially folded oligomer, andstructure. Later on, it was suggested that rifampicin
binds to A and IAPP fibrils and inhibits their contact disaggregates fibrils [13]. The baicalein quinone was
suggested to be the most “potent” baicalein form andto the neighboring cells [11, 12].
The findings of Li et al. provide strong biochemical mass spectroscopy indicated the formation of a cova-
lent baicalein quinone--synuclein adduct [13]. Conwayand biophysical evidence that rifampicin interferes with
the fibrillization pathway of -synuclein in substoichio- et al. [14] have suggested that dopamine kinetically sta-
bilizes a, potentially neurotoxic, -synuclein protofibrilmetric amounts, inhibits formation of fibrils, and can
disaggregate already formed fibrils (Figure 1) [1]. When (oligomer) by oxidative ligation to -synuclein via its
orthoquinone form. Moreover, a very recent study by Lifollowing the conformation of -synuclein in the pres-
ence of rifampicin at various time points by circular et al. has shown that dopamine can disaggregate both
-synuclein and A fibrils, suggesting the formation ofdichroism spectroscopy (CD), no changes in overall con-
formation were detected. By contrast, in the absence of covalently modified -synuclein oligomers by catechol-
amine quinone(s) [15].rifampicin, -synuclein aggregated into soluble  sheet
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Taken together, the findings by Li et al. as published Aphrodite Kapurniotu
Laboratory of Bioorganic and Medicinal Chemistryin this issue of Chemistry & Biology are exciting and
offer new mechanistic insight and potential therapeutic Institute of Biochemistry
University Hospital of the RWTH Aachenstrategies for PD. At the same time, these results in
conjunction with the above discussed findings give rise Pauwelstraße 30
D-52074 Aachento a number of questions that need to be addressed.
For example, what are the chemical and quarternary Germany
structure(s) of the -synuclein oligomers that are poten-
tially stabilized by rifampicin, baicalein, or dopamine? Selected Reading
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ogy. This is illustrated by the technological drive towardMicrobe Manufacturers
the single electron transistor and in the use of semicon-of Semiconductors ductor nanoparticles for bioimaging. It is well known
that the properties of semiconductors change as a func-
tion of size, shape, and crystallinity. Cadmium sulfide
(CdS) is a semiconductor material that has been used
Synthesis of cadmium sulfide (CdS) semiconductor for such applications as fluorescent labels and optoelec-
nanoparticles within a prokaryotic organism is re- tronic transistor components, where particles of approx-
ported for the first time by Sweeney et al. [1]. This imately 4–5 nm in diameter behave as so-called quantum
paper demonstrates the utility of microorganisms to dots (QD) [2, 3]. These particles when embedded within
perform chemistries outside the scope of their “nor- an appropriate matrix act as potential wells that confine
mal” metabolism and offers an environmentally benign and stabilize electrons in discrete energy levels. The
synthesis of CdS nanoparticles. technologically useful properties of CdS QDs are due
in part to the fact that the band-gap is tunable over a
Semiconductor nanoparticles are an extremely impor- range of 1.5–3.5 eV (i.e., visible to UV).
tant class of materials with properties that can be finely Many synthetic routes to semiconductor nanopar-
ticles involve highly toxic solvents, explosive precur-tuned through composition, size, and particle morphol-
